Vertex Pharmaceuticals

Open: 353.95 Close: 350.19 Change: -3.76

You don't have read the whole internet to decide whether to invest in Vertex Pharmaceuticals. Use an AI.

How much time have you spent trying to decide whether investing in Vertex Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals Incorporated (VRTX) stock is down -0.73% while the S&P 500 has gained 0.23% as of 2:40 PM on Wednesday, Nov 22. Sell-side analysts forecast that Vertex. Pharmaceuticals will post 13.64 EPS for the current year.

Today's News

CRISPR attributed to “reduced variable external research and manufacturing costs” R&D expenses were down 22% in the third quarter of 2023 compared to the same period in 2022. Vertex Pharmaceuticals has obtained approval from the European Commission for the label expansion of Kaftrio. Vertex Pharmaceuticals Incorporated (VRTX) stock is down -0.73% while the S&P 500 has gained 0.23% as of 2:40 PM on Wednesday, Nov 22. The company is close to another breakthrough. Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report ) last released its earnings results on Monday, November 6th. Sell-side analysts forecast that Vertex. Pharmaceuticals will post 13.64 EPS for the current year. Vertex Pharmaceuticals Inc. stock underperforms monday when compared to competitors - marketwatch.com. Q4 earnings are confirmed for February 6, 2024. Wall Street analysts predict that Vertex Pharmaceuticals s share price could reach $380.77 by Nov 22, 2024. Wall Street analyst estimates that the average VRTX share price is $353.04. Vertex Pharmaceuticals Incorporated (VRTX) has on average historically risen by 28.4% based on the past 32 years of stock performance. The current share price is $350.19, which is 52% above its historic median score of 50%.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, VRTX, stock, analyst, share, price, and the most common words in the summary are: vertex, pharmaceutical, stock, market, price, kb, pdf, . One of the sentences in the summary was: Sell-side analysts forecast that Vertex. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #market #price #kb #pdf.